ME02328B - Antivirusni 2, 5-dibenzimidazol- 5- il-1-fenil- pirolidinderivat - Google Patents

Antivirusni 2, 5-dibenzimidazol- 5- il-1-fenil- pirolidinderivat

Info

Publication number
ME02328B
ME02328B MEP-2016-14A MEP1416A ME02328B ME 02328 B ME02328 B ME 02328B ME P1416 A MEP1416 A ME P1416A ME 02328 B ME02328 B ME 02328B
Authority
ME
Montenegro
Prior art keywords
pyrrolidin
phenyl
benzimidazol
fluoro
methyl
Prior art date
Application number
MEP-2016-14A
Other languages
English (en)
Unknown language (me)
Inventor
David A Degoey
Mark A Matulenko
Ryan G Keddy
Tammie K Jinkerson
Yi Gao
Dachun Liu
John K Pratt
Todd W Rockway
Clarence J Maring
Douglas K Hutchinson
Charles A Flentge
Warren M Kati
Rolf Wagner
Michael D Tufano
David A Betebenner
Kathy Sarris
Kevin R Woller
Sebel H Wagaw
Jean C Califano
Wenke Li
Daniel D Caspi
Mary E Bellizzi
Charles W Hutchins
William A Carroll
Pamela L Donner
Allan C Krueger
John T Randolph
Christopher E Motter
Lissa T Nelson
Sachel V Patel
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/903,822 external-priority patent/US20110092415A1/en
Priority claimed from US13/100,827 external-priority patent/US8937150B2/en
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of ME02328B publication Critical patent/ME02328B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MEP-2016-14A 2010-10-13 2011-10-12 Antivirusni 2, 5-dibenzimidazol- 5- il-1-fenil- pirolidinderivat ME02328B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/903,822 US20110092415A1 (en) 2009-06-11 2010-10-13 Anti-Viral Compounds
US12/964,027 US8921514B2 (en) 2009-06-11 2010-12-09 Anti-viral compounds
US201161446800P 2011-02-25 2011-02-25
US13/100,827 US8937150B2 (en) 2009-06-11 2011-05-04 Anti-viral compounds
EP13191041.6A EP2692346B1 (en) 2010-10-13 2011-10-12 An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative

Publications (1)

Publication Number Publication Date
ME02328B true ME02328B (me) 2016-06-20

Family

ID=55069204

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-14A ME02328B (me) 2010-10-13 2011-10-12 Antivirusni 2, 5-dibenzimidazol- 5- il-1-fenil- pirolidinderivat

Country Status (18)

Country Link
JP (4) JP2016106075A (enExample)
KR (1) KR101990936B1 (enExample)
CA (1) CA2938547A1 (enExample)
CY (1) CY1117188T1 (enExample)
DK (1) DK2692346T3 (enExample)
ES (1) ES2560842T3 (enExample)
GT (1) GT201300093AA (enExample)
HR (1) HRP20151389T1 (enExample)
HU (1) HUE026832T2 (enExample)
IL (2) IL225010A (enExample)
ME (1) ME02328B (enExample)
MY (1) MY164064A (enExample)
PT (1) PT2692346E (enExample)
RS (1) RS54619B1 (enExample)
SI (1) SI2692346T1 (enExample)
TW (1) TWI621611B (enExample)
UA (1) UA113048C2 (enExample)
ZA (3) ZA201302269B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201706806D0 (en) * 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
GB202015187D0 (en) 2020-09-25 2020-11-11 Sentinel Oncology Ltd A pharmaceutical salt

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100268694B1 (ko) * 1991-10-11 2000-10-16 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 레트로바이러스 프로테아제 억제제로 유용한 시클릭 우레아 및 유사체
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010065668A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EP2853531A3 (en) * 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds

Also Published As

Publication number Publication date
MY164064A (en) 2017-11-15
RS54619B1 (sr) 2016-08-31
ES2560842T3 (es) 2016-02-23
HK1188717A1 (en) 2014-05-16
SI2692346T1 (sl) 2016-03-31
IL261206B (en) 2019-12-31
JP2021035964A (ja) 2021-03-04
TWI621611B (zh) 2018-04-21
ZA201705519B (en) 2019-04-24
UA113048C2 (xx) 2016-12-12
CA2938547A1 (en) 2012-04-19
KR101990936B1 (ko) 2019-06-19
KR20180026775A (ko) 2018-03-13
JP6586147B2 (ja) 2019-10-02
ZA201903284B (en) 2021-01-27
JP2020059696A (ja) 2020-04-16
DK2692346T3 (en) 2016-02-29
IL225010A (en) 2016-04-21
JP6790202B2 (ja) 2020-11-25
GT201300093AA (es) 2015-07-08
PT2692346E (pt) 2016-03-22
IL261206A (en) 2018-10-31
JP2016106075A (ja) 2016-06-16
CY1117188T1 (el) 2017-04-05
ZA201302269B (en) 2021-05-26
HRP20151389T1 (hr) 2016-01-15
TW201412707A (zh) 2014-04-01
JP2018065828A (ja) 2018-04-26
HUE026832T2 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
PE20140038A1 (es) Compuestos antivirales
HRP20191939T1 (hr) Postupci za liječenje hepatitisa c
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
SG10201900695PA (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
DOP2011000298A (es) Metilo[(2s)-1-{(2s)-2-[5-(10-{2-[(2s)-1-{(2s)-2-[(metoxicarbonil) amino]-3- metilbutanoilo} pirrolidina-2-yl]-1h-imidazol-5-yl}-6-fenilindol[1,2-c][1,3] benzoxazin-3-yl)-1h-imidazol-2-yl]pirrolidina-1-yl} -3-metilo-1-oxobutan-2-yl]carbamato y uso del mismo para tratar la infección por vhc
HRP20240168T1 (hr) Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
MA32633B1 (fr) Formes cristallines d'un derive 2-thiazolyl-4-quinolinyl-oxy, un inhibiteur puissant du vhc
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
UA114351C2 (uk) Поліциклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
HRP20171898T1 (hr) Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika
JP2009500443A5 (enExample)
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
MX2010008148A (es) Métodos de tratamiento de infecciones virales.
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
PE20142439A1 (es) Formulacion en capsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dietiletilo
EA201390233A1 (ru) Фармацевтические композиции
HRP20110713T1 (hr) Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
JP2006507295A5 (enExample)
HRP20151389T1 (hr) Antivirusni 2,5-dibenzimidazol-5-il-1-fenil-pirolidinderivat
CL2011001764A1 (es) Composicion farmaceutica que comprende (2r,3r,4r,5r)-5-(4-amino-2-oxo-2h-pirimidin-1-il)-4-fluoro-2-isobutiriloximetil-4-metil-tetrahidro-furan-3-il ester de acido isobutirico e hidroxipropilcelulosa; y uso en el tratamiento de una enfermedad mediada por el virus de la hepatitis c.
ATE534375T1 (de) Pharmazeutische zusammensetzung mit n-ä2- (diethylamino)ethylü-5-ä(5-fluoro-1,2- dihydro-2- oxo-3h-indol-3-yliden)methylü-2,4-dimethyl-1h- pyrrol-3-carbonsäureamid
MA34548B1 (fr) Formes solides d'un inhibiteur puissant du vhc